Skip to main content

NCT00297388 - A 52-wk Prospective, Randomized, Double-blind, Multicenter Study of Relapse Following Transition From Oral Antipsychotic Medication to 2 Different Doses (25 or 50 mg Every 2 Wks) of Risperidone Long-acting Microspheres (RISPERDAL CONSTA) i

A 52-wk Prospective, Randomized, Double-blind, Multicenter Study of Relapse Following Transition From Oral Antipsychotic Medication to 2 Different Doses (25 or 50 mg Every 2 Wks) of Risperidone Long-acting Microspheres (RISPERDAL CONSTA) in Adults With Schizophrenia or Schizoaffective Disorder


CSR Summary

Not Yet Available


Data Specification

Not Available


Annotated CRF

Not Available

Product Info

Generic Name
Risperidone
Product Name
RISPERDAL CONSTA®
Therapeutic Area
Behaviors and Mental Disorders
Enrollment
40
% Female
37.7%
% White
49.4%
Product Class
Atypical Antipsychotics
Sponsor Protocol Number
RIS-SCH-401
Data Partner
Johnson & Johnson
Condition Studied
Schizophrenia
Mean/Median Age (Years)
40.9

Supporting Documentation

Clinical Study Report
Collected Datasets
Data Definition Specification
Annotated Case Report Form
Protocol with Amendments

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.